Posted inGenetics
Public Model for Predicting Long-Term Cell Stability
Scientists from the Massachusetts Institute of Technology (MIT) have developed the first publicly available model for predicting the long-term stability…
Posted inGenetics
People Power in AI’s Penetration in Bioprocessing
Artificial intelligence (AI) is changing biotechnology from agriculture to bioprocessing and much more. Still, it’s a little hard to put…
Posted inGenetics
Precision Microfluidics for RNA and Gene Therapy Applications
Sponsored content brought to you by As nucleic acid–based therapeutics evolve and mature, so too must the analytical tools that…
Posted inBiotechnology
LB Pharmaceuticals aims for $228M-plus IPO to fund late-stage schizophrenia study
Despite the stagnant biotech IPO market of the last six months, LB Pharmaceuticals has set out plans to reel in…
Posted inMedical Technology
Microbot Medical scores FDA clearance for remote-controlled cath lab system
Microbot Medical has received the FDA’s blessing for its miniature, remote-controlled robot for endovascular procedures, designed to offer clinicians the…
Posted inBiotechnology
After FDA rejects Saol’s ultra-rare disease prospect, advocacy groups urge patients to press Congress
After previously delaying its decision date, the FDA has outright rejected Saol Therapeutics’ investigational treatment for an ultra-rare pediatric mitochondrial…
Posted inBiotechnology
Regeneron’s allergen-blocking antibodies score phase 3 wins against cat, pollen allergies
Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen allergies in a pair of phase 3 studies. One…
Posted inBiotechnology
Dianthus’ gMG prospect blooms, with phase 2 win setting up pivotal plans
Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase…
Posted inBiotechnology
Atom claims phase 3 win shows gout drug can beat competition in efficacy, safety
Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and…
Posted inBiotechnology
Rapport’s seizure drug hits in phase 2, sending stock soaring
A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in…